spacer
home > pmps > spring 2018 > seamless serialisation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Seamless Serialisation

The introduction of serialisation, designed to ensure the authenticity and traceability of individual medicines, promises to improve patient safety and create exciting opportunities for digital health, but there is a twist. Failure to comply with the mandated EU regulation means a company cannot legally ship their product – no barcode, no trade. That is when a serial drama turns into a tragedy, and time is running out to be ready. The Falsified Medicines Directive (FMD) imposes strict serialisation requirements on pharmaceutical manufacturers, distributors, and dispensers.

The FMD, first introduced in 2011, is now heading into its final phase. The denouement arrives on 9 February 2019 when the Directive is fully enforced and the noncompliance penalties officially come into play. The FMD aims to prevent inauthentic, substandard, or harmful medicines entering the supply chain by imposing strict serialisation, traceability, and verification requirements on pharma manufacturers and their associated wholesalers, distributors, and contract manufacturers. In particular, it requires companies to print a unique identifier on the packaging of prescription medicines. Furthermore, companies are not just responsible for the data on the packaging, they are responsible for submitting it to the central data hub that will enable pharmacists to authenticate products before dispensing them. It is a complex undertaking that could be easily underestimated, but understanding some key steps can prevent this.

The implementation of serialisation is not an overnight task. It encompasses processes that have multiple touchpoints across global organisations, partner networks, and the wider supply chain. Despite this and the enormous implications of getting it wrong, many companies are still some distance from being fit-for-purpose. Indeed, in some organisations, the Directive has not yet hit their radar – but it needs to because the clock is ticking. Nevertheless, all is not lost.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Davison is Head of EU at rfxcel. He is an expert, speaker, and writer in the pharma and product security industry. Mark is a board-level operator specialising in strategic global health and Big Data issues such as serialisation, supply chain security, patient safety, and government policy. Additionally, he has a wide experience elsewhere including due diligence and international business development. Mark also has technical expertise in anti-counterfeiting technologies and vendor selection, including authentication, serialisation, and traceability and is an expert in legislation and its impact. He is currently based in the UK, with wide experience in Europe, Africa, Asia (including Japan and China), as well as North and South America. 
spacer
Mark Davison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement